Add as a preferred source on Google

Lexeo Trial Data Leads Raymond James and Cantor Fitzgerald to Raise Targets

The target changes followed interim data from a Phase I/II trial of LX2020 for PKP2 arrhythmogenic cardiomyopathy. Raymond James views Lexeo as a strong buy.

An anatomical heart model rests beside ECG leads in a research suite / TokenPost.ai
An anatomical heart model rests beside ECG leads in a research suite / TokenPost.ai

Raymond James and Cantor Fitzgerald raised their price targets for Lexeo Therapeutics (LXEO) after interim data from a Phase I/II trial of LX2020 for PKP2 arrhythmogenic cardiomyopathy.

Raymond James views Lexeo as a strong buy.

Loading…